



End-term Project final report

Sun pharma financial analysis
Guided by RanaPratap sir

By Ankith Jain(em23mtech14004)



STARTUP FINANCING FINAL ASSIGNMENT REPORT

1.Introduction: sun pharma

Sun Pharma, a flagship company of the Sun Group, stands as a cornerstone in India's pharmaceutical landscape, commanding a formidable presence both domestically and on the global stage. With a rich history spanning several decades, Sun Pharma has carved a niche for itself by relentlessly pursuing excellence in research, development, and manufacturing of high-quality pharmaceutical products. Guided by a vision to emerge as a global leader in healthcare, Sun Pharma has consistently demonstrated its commitment to delivering innovative and affordable solutions to address the healthcare needs of millions worldwide.

At the heart of Sun Pharma's operations lies a steadfast dedication to innovation, exemplified by its robust research and development pipeline, which continuously churns out breakthrough products across a wide spectrum of therapeutic areas. From generics to specialty pharmaceuticals, Sun Pharma's diverse portfolio caters to a multitude of medical needs, ranging from chronic diseases to acute ailments. This expansive product range not only reinforces Sun Pharma's position as a comprehensive healthcare provider but also underscores its agility in adapting to evolving market demands and technological advancements.

Beyond its commercial endeavors, Sun Pharma places a strong emphasis on corporate sustainability and social responsibility. The company's commitment to ethical business practices, environmental stewardship, and community engagement has earned it accolades and recognition from industry peers and regulatory bodies alike. By integrating sustainability into its core business strategy, Sun Pharma not only enhances its brand reputation but also contributes to the greater societal good, thereby fostering a sustainable future for generations to come.

Against this backdrop, this report endeavors to delve into Sun Pharma's financial performance during the period from January 1st, 2024, to March 31st, 2024. By meticulously analyzing key financial metrics and performance indicators, this report seeks to offer valuable insights into Sun Pharma's financial health, profitability, and investment potential. Additionally, by juxtaposing Sun Pharma's financial performance with that of the market benchmark (Nifty50), this report aims to provide a comprehensive assessment of Sun Pharma's relative performance and investment attractiveness in the pharmaceutical sector.

By undertaking this comprehensive analysis, stakeholders can gain a deeper understanding of Sun Pharma's financial dynamics and strategic positioning, thereby enabling them to make informed investment decisions and navigate the intricacies of the pharmaceutical market with confidence and clarity.

2. Financial Observations and Interpretations

The financial metrics derived from the spreadsheet analyses offer valuable insights into Sun Pharma's performance during the specified period:

2.2 Average Return: The average return of 0.45% reflects the mean rate of return achieved by Sun Pharma's stock over the analyzed period. This metric provides an indication of the company's performance relative to its market peers and benchmarks.

2.3 Variance: With a variance of 0.00018245, Sun Pharma's stock exhibits a degree of dispersion or volatility around its average return. A higher variance suggests greater volatility in stock returns, indicating potential fluctuations in the company's performance.

2.4 Standard Deviation: The standard deviation of 0.013507394 measures the extent of variability or dispersion of Sun Pharma's stock returns from the average return. It provides insights into the risk associated with investing in the company's stock, with a higher standard deviation indicating greater risk.

2.5 Return on Equity (ROE): Sun Pharma's ROE of 14.99% signifies the company's ability to generate profits from shareholders' equity. A higher ROE indicates efficient utilization of shareholder funds and suggests a favorable return on investment for equity holders.

2.6 Price-to-Earnings (P/E) Ratio: The P/E ratio of 43.37 reflects the market's valuation of Sun Pharma's stock relative to its earnings per share (EPS). A higher P/E ratio typically

indicates that investors are willing to pay a premium for the company's future earnings growth potential.

2.7 Gross Profit Ratio: Unfortunately, the gross profit ratio is not provided in the analysis, which could be a limitation in assessing Sun Pharma's profitability. The gross profit ratio measures the proportion of revenue that exceeds the cost of goods sold and is an important indicator of the company's operational efficiency and profitability.

2.8 Earnings Per Share (EPS): Sun Pharma's EPS of 37.17 indicates the company's profitability on a per-share basis. It represents the portion of the company's net income attributable to each outstanding share of common stock and is a key determinant of stock valuation.

2.9 Return on Assets (ROA): With an ROA of 15.13%, Sun Pharma demonstrates its ability to generate profits from its assets. This metric assesses the company's efficiency in utilizing its assets to generate earnings and provides insights into its operational performance.

2.10 Enterprise Value: Sun Pharma's enterprise value of 3.72 trillion reflects the total value of the company, including both its equity and debt, as perceived by the market. It provides a comprehensive measure of Sun Pharma's overall worth to potential acquirers or investors.

32% Revenue share	₹ 136,031 Million Revenue in FY23	#1 Rank with 8.3% market share
#1 Rank by prescription with 12 different classes of doctors	32 Brands among India's top 300 brands	12,600+ Strong field force

3.Comparison with Market Benchmark (Nifty50)

The comparison of Sun Pharma's financial performance metrics with the market benchmark (Nifty50) provides valuable insights into the company's relative performance and attractiveness as an investment opportunity.

Expected Return Through CAPM:

The expected return of 6.014% through the Capital Asset Pricing Model (CAPM) with respect to the Nifty50 index serves as a benchmark for evaluating Sun Pharma's performance against the broader market. This metric represents the anticipated return

that investors could expect from investing in an asset with a similar level of risk as the Nifty50 index.

Relative Strength in ROE and ROA:

Comparing Sun Pharma's ROE and ROA with the market benchmark reveals that the company outperforms the market average in both metrics. Sun Pharma's higher ROE and ROA indicate its relative strength in generating profits from shareholders' equity and assets, respectively. This suggests that Sun Pharma is more efficient in utilizing its resources to generate returns for shareholders compared to the broader market.

Perception of Growth Prospects:

However, Sun Pharma's P/E ratio is higher than the market average, indicating that investors perceive the company's growth prospects and future earnings potential more positively than the market as a whole. A higher P/E ratio suggests that investors are willing to pay a premium for Sun Pharma's stock relative to its earnings, reflecting optimism about the company's growth trajectory and future profitability.

Overall Assessment:

In summary, while Sun Pharma demonstrates strength in key financial metrics such as ROE and ROA compared to the market benchmark, the higher P/E ratio suggests that the market views the company's growth prospects favorably. This indicates that Sun Pharma may offer attractive investment opportunities for investors seeking exposure to the pharmaceutical sector, driven by its robust financial performance and positive market sentiment. However, investors should conduct thorough due diligence and consider the company's risk factors and competitive positioning before making investment decisions.

In conclusion, Sun Pharma's financial analysis for the period from January 1st, 2024, to March 31st, 2024, paints a picture of stability with moderate volatility. Key indicators such as ROE, ROA, and the P/E ratio suggest positive aspects of the company's performance, signaling its ability to generate returns for shareholders and maintain efficient asset utilization. However, the absence of the gross profit ratio limits a comprehensive assessment of Sun Pharma's profitability, highlighting the need for further monitoring and analysis in this regard.


Recommendations for Investors and Stakeholders:

Monitor Gross Profit Ratio: Keep a close watch on Sun Pharma's gross profit ratio to better understand its profitability trends and assess the effectiveness of its revenue generation and cost management strategies.

Evaluate Performance Relative to Benchmark: Continuously assess Sun Pharma's performance relative to the market benchmark (Nifty50) to gauge its investment attractiveness and identify any deviations or trends that may affect its long-term prospects.

Consider Growth Prospects: Take into account Sun Pharma's growth prospects and future earnings potential, as reflected in its P/E ratio. Assess the sustainability of these growth factors and their alignment with the company's strategic objectives.

Assess R&D Capabilities and International Presence: Evaluate Sun Pharma's research and development capabilities and its expansion efforts in international markets to gain insights into its competitive position and potential for future growth.



4.Potential Areas of Improvement and Risks:

Managing Volatility: Sun Pharma should focus on managing volatility in its financial performance to ensure stability and consistency over time, thereby enhancing investor confidence and reducing market uncertainty.

Improving Profitability: Explore opportunities to optimize cost structures, increase operational efficiency, and diversify revenue streams to enhance profitability and strengthen the company's financial position.

Addressing Regulatory and Competitive Challenges: Proactively address regulatory compliance issues and navigate competitive pressures within the pharmaceutical industry to mitigate risks and sustain growth momentum.

Investing in R&D: Continue to invest in research and development initiatives to drive innovation, develop new products, and maintain a competitive edge in the market, thereby securing long-term success and market leadership.

By implementing these recommendations and addressing potential areas of improvement and risks, Sun Pharma can enhance its financial performance, bolster investor confidence, and position itself for sustained growth and success in the dynamic pharmaceutical landscape.



Reference :

1. <https://finance.yahoo.com/quote/SUNPHARMA.NS/financials>
2. https://www.wsj.com/search?query=sun%20pharma&mod=searchresults_viewallresults
3. <https://www.alphaspread.com/security/nse/sunpharma/financials/income-statement>
4. <https://www.master-of-finance.org/lists/5-industries-that-employ-financial-analysts/>
5. <https://www.bibs.co.in/blog/indias-top-15-high-paying-finance-careers>

EM23MTECH14004
ANKITH JAIN S

6. <https://www.bibs.co.in/blog/indias-top-15-high-paying-finance-careers>